Victory Square Technologies Updates Investors on Healthcare and Hydreight Investments Following FDA Recommendations

Victory Square Technologies Inc. Update on Healthcare Investments

Victory Square Technologies Inc. (commonly referred to as VST) has recently provided a significant update concerning its investments in the healthcare sector, especially in relation to Hydreight Technologies Inc. Following the advisory committee recommendations from the U.S. Food and Drug Administration (FDA) regarding peptide-related bulk drug substances, shareholders are keen to understand the implications of these developments.

Hydreight Technologies and Its Position

As the largest shareholder of Hydreight, Victory Square holds approximately 44.5% of the company's common shares, totaling 23,891,515 shares. Hydreight Technologies has made strides as a digital healthcare platform that bridges healthcare providers, pharmacies, and patients across the U.S. A notable aspect of this platform is its extensive network, boasting over 12,000 VSDHOne licenses, operations in all 50 states, and a partnership with more than 300 licensed physicians and 3,000 nurses. The platform also supports over 45 treatment offerings supervised by medical professionals, ranging from GLP-1 therapies to peptide-based treatments and more.

During its recent meeting on July 23-24, 2026, the FDA’s Pharmacy Compounding Advisory Committee recommended the inclusion of six peptide-related bulk drug substances on the Section 503A Bulks List, excluding Emideltide. Although these recommendations carry no binding authority, they could influence future regulatory processes that may impact Hydreight and, by extension, Victory Square's investment strategy.

Insights into Hydreight's Regulatory Journey

In response to the FDA's recommendations, Hydreight has vowed to remain vigilant, continuously reassessing the regulatory landscape while leveraging its resources. By collaborating with its clinical and legal partners, Hydreight aims to explore potential opportunities that may arise from this evolving situation.

Significant Investments by Victory Square

1. Hydreight Technologies

Victory Square's focus on healthcare investment has led to substantial capital being directed into Hydreight. This investment helps facilitate the company’s operations in telehealth and healthcare personalization. Peptide-based therapies like Sermorelin and Ipamorelin are part of the offerings provided through Hydreight's services, reflecting a commitment to innovative healthcare solutions.

2. Insu Therapeutics

Another noteworthy investment is in Insu Therapeutics, which is dedicated to developing a buccal drug delivery platform specifically for peptide and biologic molecules. This technology promises a needle-free administration route, reducing common concerns associated with traditional injections and oral medications. Insu's innovative approach could revolutionize how peptide therapies are delivered, a factor that Victory Square closely monitors.

3. Pawsible Ventures

Victory Square is also committed to advancing companion animal health through its initiative, Pawsible. This venture emphasizes technology-enabled veterinary care, diagnostics, and preventative health solutions, highlighting the company’s broad vision in the healthcare sector.

Upcoming Shareholder Engagement

To further engage with its investors, Victory Square is set to host a live shareholder webinar on August 5, 2026. This session will feature updates from Insu Therapeutics concerning its innovative drug delivery technologies and an open Q&A to address any inquiries shareholders may have. This proactive communication strategy aims to foster greater transparency and stakeholder confidence within the rapidly changing healthcare landscape.

Conclusion

As Victory Square Technologies moves forward amidst regulatory challenges and market opportunities, its strategic investments in Hydreight and Insu Therapeutics among others remain pivotal. The broader implications of the FDA’s recommendations will undoubtedly shape the future trajectory of these investments, making it essential for stakeholders to stay informed and engaged.

For more details, shareholders can register for the upcoming webinar at here. Victory Square encourages stakeholders to direct any questions to their designated contact point, ensuring that communication lines remain open and informative.

Stay updated with the latest developments at Victory Square Technologies Inc., where innovation meets healthcare investments.